

**The Effect Profitability Ratio On Pharmaceutical Company Listed
On The Indonesia Stock Exchange Period 2017-2022**



SKRIPSI

Disusun untuk Memenuhi Syarat Menyelesaikan Pendidikan Sarjana Terapan
(D-IV) Akuntansi Sektor Publik pada Jurusan Akuntansi
Politeknik Negeri Sriwijaya

OLEH:
RAZITA NUR SABRINA

061940512501

**POLITEKNIK NEGERI SRIWIJAYA
PALEMBANG
2024**

**The Effect Profitability Ratio On Pharmaceutical Company Listed
On The Indonesia Stock Exchange Period 2017-2022**



SKRIPSI

Disusun untuk Memenuhi Syarat Menyelesaikan Pendidikan Sarjana Terapan
(D-IV) Akuntansi Sektor Publik pada Jurusan Akuntansi
Politeknik Negeri Sriwijaya

OLEH:
RAZITA NUR SABRINA
061940512501

POLITEKNIK NEGERI SRIWIJAYA
PALEMBANG
2024

DECLARATION

With this, I declare that the work has been carried out by the regulations of Management and Science University. This results is original from my own work and that no part of the work on this thesis has been submitted in support of the application for any other degree or diploma from this university or any other university or institution of learning.

I hereby declare that have been supplied with the Academic Rules and Regulations for Under Graduate, Management and Science University, regulating the conduct of my study and research.

Name of students	:	Razita Nur Sabrina
Student Number	:	012023091734
Programme	:	Bachelor in Accounting and Finance
Faculty	:	Faculty of Business Management and Professional
Studies Research Title	:	The Effect Profitability Ratio on Pharmaceutical Company Listed On The Indonesia Stock Exchange Period 2017 – 2022
Signature of Student	:	 Razita Nur Sabrina
Date	:	September 2024



LEMBAR PENGESAHAN SKRIPSI

Nama : Razita Nur Sabrina
NIM : 061940512501
Jurusan : Akuntansi
Program Studi : D-IV Akuntansi Sektor Publik
Mata Kuliah : Analisis Laporan Keuangan
Judul Skripsi : The Effect Profitability Ratio on Pharmaceutical Company Listed On The Indonesia Stock Exchange Period 2017 – 2022


Telah Diujikan Pada Ujian Skripsi/*Colloquium* Tanggal 28 Agustus 2023

Dihadapan Tim Pengaji Jurusan Akuntansi


Politeknik Negeri Sriwijaya dan Management & Science University

Palembang, September 2024

Pembimbing I,


Nur Shafiqah Binti Kapeli
Employee No. S012023010011

Pembimbing II,


Dr. Maria, S.E., M.Si., Ak., CA
NIP 196611181997022001

Mengetahui,
Ketua Jurusan Akuntansi,


Dr. Evada Dewata, S.E., M.Si., Ak., CA.
NIP 197806222003122001

KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
POLITEKNIK NEGERI SRIWIJAYA



JURUSAN AKUNTANSI

Jalan Srijaya Negara, Palembang 30139

Telp. 0711-353414 Fax. 0711-355918

Website : www.polsri.ac.id E-mail: akuntansi@polsri.ac.id



SURAT PERNYATAAN BEBAS PLAGIARISME

Yang bertanda tangan di bawah ini :

Nama : Razita Nur Sabrina
NIM : 061940512501
Jurusan/Program Studi : Akuntansi/D-IV Akuntansi Sektor Publik
Judul Skripsi : The Effect Profitability Ratio on Pharmaceutical Company Listed On The Indonesia Stock Exchange Period 2017 – 2022

Dengan ini menyatakan :

1. Skripsi yang saya buat dengan judul sebagaimana tersebut di atas beserta isinya merupakan hasil penulisan saya sendiri.
2. Skripsi tersebut bukan plagiat atau menyalin skripsi milik orang lain.
3. Apabila skripsi ini di kemudian hari dinyatakan plagiat atau menyalin skripsi milik orang lain, maka saya bersedia menanggung konsekuensinya.

Demikian surat pernyataan ini saya buat dengan sebenarnya dalam keadaan sadar, untuk diketahui dan digunakan sebagaimana mestinya.

Palembang, September 2024

Yang Membuat Pernyataan,

Razita Nur Sabrina

NIM 061940512501





LEMBAR PELAKSANAAN REVISI SKRIPSI

Mahasiswa berikut,

Nama : Razita Nur Sabrina

NIM : 061940512501

Jurusan/Program Studi : Akuntansi/D-IV Akuntansi Sektor Publik

Judul Skripsi : The Effect Profitability Ratio on Pharmaceutical Company
Listed On The Indonesia Stock Exchange Period 2017 –
2022

Telah melaksanakan revisi terhadap Skripsi yang diujikan pada hari Senin tanggal 9 bulan September tahun 2024. Pelaksanaan revisi terhadap Skripsi tersebut telah disetujui oleh Dosen Penguji yang memberikan revisi.

No.	Komentar	Nama Dosen Penguji	Universitas	Tanggal	Tanda Tangan
1.	-	Ap Dr Azam Employee No. S012023070009	Management & Science University	3/5/2024	
2.	-	Yuliana Sari, S.E., MBA., Ak., CA NIP 197707292008012015	Politeknik Negeri Sriwijaya	3/5/2024	

ACKNOWLEDGEMENT

Assalamualaikum warahmatullahi wabarakatuh.

By saying Alhamdulillah, all praise and gratitude goes to Allah SWT, because through His grace and guidance the research methodology entitled "The Effect of Profitability Ratios on Pharmaceutical Companies Listed on the Indonesian Stock Exchange 2017-2022 Period" can be successfully completed, fulfill one of the graduation requirements.

The author encountered many obstacles and challenges during the writing of this thesis. However, thanks to the help of many parties, this research methodology could be completed successfully. Therefore, with all humility, the author expresses his thanks.

First of all, the author would like to express his sincere thanks to my parents who always prayed for, encouraged and supported me during my studies. Furthermore, deepest thanks are expressed to the research supervisor, Mrs. Shafiqah Binti Kapeli, as well as to the research project lecturer, Dr. Siti Fatimah Mohd Kassim and Dr. Rami Salmeen Mohammed, for his guidance during the preparation of the Research Methodology until the final stage. We also express our deepest gratitude to Sakti Adzie Prawira who has provided endless support during the preparation of this thesis.

The author realizes that perfection is impossible to achieve in preparing this research methodology. Therefore, the author apologizes for the shortcomings and errors.

"To all parties involved, the author hopes that this thesis will be useful for readers and become a valuable reference for further development."

ABSTRACT

The Effect Profitability Ratio On Pharmaceutical Company Listed On TheIndonesia Stock Exchange Period 2017-2022

Razita Nur Sabrina, 2024 (xi + 43 pages)

Email: Razitanursab21@gmail.com

This study investigates how Return on Assets (ROA), Return on Equity (ROE), and Price Earnings Ratio (PER) influence the stock prices of pharmaceutical companies on the Indonesia Stock Exchange (IDX) between 2017 and 2022. Analyzing ROA during this period provides insights into the operational leverage of these companies and its correlation with stock price fluctuations. ROE assesses how efficiently a company uses its equity capital to generate profits, offering a view of its profitability relative to shareholder equity. Variations in ROE may affect investors' sentiments and influence stock prices, demonstrating the relationship between ROE and stock prices within the given timeframe. PER compares a company's stock price to its earnings per share, making it a significant valuation metric. A high Price Earnings Ratio typically indicates that investors expect future earnings to increase. Tracking the PER of pharmaceutical companies on the IDX from 2017 to 2022 helps understand investor perceptions and anticipations, with PER fluctuations signaling shifts in market sentiment and impacting stock valuations. This study employs a multiple linear regression method to analyze financial statements, market information, and stock prices of nine pharmaceutical firms listed on the IDX between 2017 and 2022. Classical assumption tests, including normality, multicollinearity, and autocorrelation tests, were conducted to ensure the reliability of the regression analysis. Data analysis was performed using Microsoft Excel and SPSS.

Keywords: Return on Assets (ROA), Return on Equity (ROE), Price Earnings Ratio (PER), Stock Exchange(IDX), pharmaceutical sector.

TABLE OF CONTENT

COVER PAGE	i
INNER COVER PAGE	ii
SURAT PERNYATAAN BEBAS PLAGIARISM.....	III
DECLARATION.....	IV
LEMBAR PENGESAHAN SKRIPSI.....	V
LEMBAR PELAKSANAAN REVISI SKRIPSI.....	VI
ACKNOWLEDGEMENT	VII
ABSTRACT	VIII
TABLE OF CONTENT	IX
LIST OF TABLES	XI
CHAPTER I INTRODUCTION.....	1
1.1 Background of Study	1
1.2 Problem Statement	1
1.3 Research Objective and Questions.....	3
1.4 Research Questions.....	3
1.5 Significance of the Study.....	4
1.6 Scope of Study	4
CHAPTER II LITERATURE REVIEW	6
2.1 Literature Review.....	6
2.1.1 Stock Prices	6
2.1.2 Return on Assets (ROA).....	7
2.1.3 Return on Equity (ROE)	8
2.1.4 Price Earnings Ratio (PER).....	9
2.2 Underpinning Theory and Signaling Theory.....	10
2.3 Research Framework	10
2.4 Research Hypothesis.....	11
CHAPTER III RESEARCH METHODOLOGY	12
3.1 Research Design	12
3.2 Method of the Research	12
3.3 Population and Sample	12
3.4 Measurement of variable.....	12
3.5 Data Collection	13
3.6 Sampling Procedure	14
3.6.1 Target Population	14
3.6.2 Unit analysis	14
3.6.3 Method of Sampling	14
3.7 Sample Size	14

3.8 Data Analysis Techniques	15
3.8.1 Descriptive Analysis Of Data.....	15
3.8.2 Multiple Linear Regression Analysis	15
3.8.3 Coefficient Of Determination (R Square).....	15
3.8.4 Classic Assumption Test.....	17
3.8.5 Normality Test.....	17
3.8.6 Multicollinearity Test	17
3.9 Hypotheses Test.....	18
3.9.1 T Test.....	18
3.9.2 F Test	18
CHAPTER IV RESULT AND DISCUSSION.....	20
4.1 Company Overview	20
4.1.1 Darya-Varia Laboratoria Tbk	20
4.1.2 Indofarma Tbk.....	21
4.1.3 Kimia Farma Tbk	21
4.1.4 Kalbe Farma Tbk	22
4.1.5 Merck Tbk	23
4.1.6 Phapros Tbk.....	23
4.1.7 Pyridam Farma Tbk	24
4.1.8 Industri Jamu dan Farmasi Sidomuncul.....	25
4.1.9 Tempo Scan Pacific Tbk.....	25
4.2 Descriptive Analysis Of Data	27
4.3 Classic Assumption Test	28
4.3.1 Normality Test.....	28
4.3.2 Multicollinearity Test	29
4.4 Multiple Linear Regression Analysis.....	30
4.5 Coefficient Of Determination (R Square)	31
4.6 Hypotheses Test.....	31
4.6.1 T-Test.....	31
4.6.2 F-Test	32
4.7 Discussions.....	33
4.7.1 The influence of Return on Equity (ROE) on Stock Price	33
4.7.2 The influence of Return on Assets (ROA) on Stock Price	34
4.7.3 The influence of Price Earning Ratio (PER) on Stock Price	35
CHAPTER V CLOSURE	37
5.1 Overview of Study	37
5.2 Summary of Research Findings.....	37
5.3 Contribution of Study	38

5.3.1 Body of Knowledge	38
5.3.2 Theory.....	39
5.3.3 Practical	39
5.4 Limitation of The Study	39
5.5 Future Research	39
REFERENCES.....	41
LAMPIRAN.....	44

LIST OF TABLES

Table 4. 1 Descriptive Statistical Analysis Results.....	27
Table 4. 2 Normality Test Result	28
Table 4. 3 Normality Test Results After Data Transformation.....	29
Table 4. 4 Multicollinearity Test Result	29
Table 4. 5 Multiple Linear Regression Analysis Result	30
Table 4. 6 The Result Of The Coefficient Of Determination (R-squared)	31
Table 4. 7 T-Test Result.....	32
Table 4. 8 F-Test Result	33
Table 5. 1 Result of Findings.....	37